| Introduction | For Patients | For Science | For Society | Looking Ahead From Surveillance to Vaccine Readiness Influenza pandemic preparedness begins long before an outbreak occurs. Through ongoing surveillance, scientific partnerships and investment in advanced manufacturing capabilities, CSL Seqirus monitors emerging influenza threats and maintains the expertise, infrastructure and global production network needed to respond rapidly when a novel virus emerges. This end-to-end approach, from identifying potential pandemic strains through to developing, manufacturing and supplying vaccines at scale, helps strengthen global health security and supports more equitable access to pandemic vaccines when they are needed most. Based on this foundation, CSL Seqirus continues to work with governments, public health agencies and international organisations to improve preparedness and help protect communities around the world. CSL’s new Tullamarine manufacturing facility is set to strengthen Australia’s health security and support global pandemic preparedness. The site uses advanced, scalable technology to enable year-round vaccine production and rapid response during emerging health threats. The digitally connected facility features automated, paperless manufacturing systems and advanced analytics to optimise production, quality and supply reliability. Supporting a A$300 million AUD vaccine and antivenom supply chain, the site brings together hundreds of experts to deliver influenza and other vaccines. A New Era of Vaccine Manufacturing in Australia 18 | CSL IMPACT REPORT 2026
RkJQdWJsaXNoZXIy MjE2NDg3